{"classes":[{"categories":[{"measurements":[{"comment":"There were not enough events to estimate the upper limit of the 80% confidence interval.","groupId":"OG000","lowerLimit":"4.89","upperLimit":"NA","value":"9.55"},{"comment":"Estimation of the median and the 80% confidence interval limits (lower and upper) was not possible as the participant did not achieve the event and was censored.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"DoR is defined as the time from the date that measurement criteria for CR or PR (whichever is first recorded) are first met until the first date that disease is recurrent or objective disease progression is observed, per RECIST 1.1 criteria, or the date of death from any cause in the absence of documented disease progression or recurrence .Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).","dispersionType":"80% Confidence Interval","groups":[{"description":"Participants received the following treatments in a 28-day cycle, continuing until disease progression or a criterion for discontinuation was met.\n\n* Ramucirumab administered intravenously at a dose of 12 mg/kg as a one-hour infusion on days 1 and 15.\n* Cyclophosphamide administered orally at 25 mg/m² daily from days 1 to 28.\n* Vinorelbine administered intravenously at 25 mg/m² on days 1, 8, and 15.","id":"OG000","title":"Ramucirumab + Cyclophosphamide + Vinorelbine"},{"description":"Participants received the following treatments in a 28-day cycle, continuing until disease progression or a criterion for discontinuation was met.\n\n* Cyclophosphamide administered orally at 25 mg/m² daily from days 1 to 28.\n* Vinorelbine administered intravenously at 25 mg/m² on days 1, 8, and 15.","id":"OG001","title":"Cyclophosphamide + Vinorelbine"}],"paramType":"MEDIAN","populationDescription":"All randomized participants who received at least one dose of study drug and who had CR or PR responses (including the censored participants). Number of participants censored in Ramucirumab + Cyclophosphamide + Vinorelbine = 0, Cyclophosphamide + Vinorelbine = 1.","reportingStatus":"POSTED","timeFrame":"Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Up To 23 Months)","title":"Duration of Response (DoR)","type":"SECONDARY","unitOfMeasure":"Months"}